Published in Gene Therapy Weekly, December 26th, 2002
A total of approximately 55 patients at 13 sites throughout the United States will participate in the study.
In the phase II study, TNFerade will be added to the current standard of care, which is a chemotherapeutic regimen of cisplatin/5-FU and radiation therapy followed by surgery. The primary endpoint will be complete tumor response, which will be determined through surgical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.